News Breaks |
|
|
| December 19, 2012 |
| 08:02 EDT |  | CEMP | Cempra initiates Phase 3 trial of solithromycin
Cempra announced the initiation of its global Phase 3 clinical trial of orally-administered solithromycin, the company's fluoroketolide antibiotic candidate, in patients with community-acquired bacterial pneumonia. The Phase 3 study is a double-blind, placebo-controlled and global multi-center study in which approximately 800 patients with PORT-II to PORT-IV CABP will be randomized to receive either oral solithromycin, an 800 mg loading dose followed by 400 mg once daily for a total of five days, or once-daily oral administration of 400 mg of moxifloxicin for seven days. The primary endpoint will be non-inferiority of early response at 72 hours, which is specified by the proposed FDA guidance. |
|
|
News For CEMP From The Last 14 Days Check below for free stories on CEMP the last two weeks. |
|
|
| May 20, 2013 |
| 08:03 EDT | | CEMP | Cempra announces favorable data in Phase 2 clinical trial of solithromycin
 Subscribe for More Information |
|
| May 17, 2013 |
| 10:07 EDT |  | CEMP | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| 05:34 EDT | | CEMP | Cempra initiated with a Buy at Jefferies
Subscribe for More Information |
|
| May 14, 2013 |
| 11:44 EDT | | CEMP | Cempra in licensing agreement with Japan's Toyama chemical
Subscribe for More Information |
|
| May 13, 2013 |
| 17:55 EDT |  | CEMP | Cempra has webcast replay of corporate update conference call
Webcast replay of conference call will be available until June 13. Webcast Link |
|
| 16:16 EDT | | CEMP | Cempra signs agreement with FujiFilm Holdings subsidiary
Subscribe for More Information |
|
|
|
|
|
